Sales & Marketing News | pharmaphorum

News

BMS feels the pain of Revlimid erosion, cutting forecasts

Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.

News

Merck's challenge to Pfizer's Prevnar grows

Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu

News

Roche removes tenecteplase from phase 3 for stroke

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects.

News

Jardiance cleared in EU for CKD, challenging Forxiga

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the

News

Tarsus gets first FDA nod for mite blepharitis therapy

A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US.<

News

Biogen wields axe again ahead of Leqembi rollout

Biogen has announced another big round of layoffs and cost-cutting, with 1,000 more workers set to lose their jobs after it shed around 900 last year and shelved various R

BMS feels the pain of Revlimid erosion, cutting forecasts

Merck's challenge to Pfizer's Prevnar grows

Roche removes tenecteplase from phase 3 for stroke

Jardiance cleared in EU for CKD, challenging Forxiga

Tarsus gets first FDA nod for mite blepharitis therapy

Biogen wields axe again ahead of Leqembi rollout

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks